Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses
Open Access
- 11 April 2017
- journal article
- review article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 17 (1) , 1-11
Abstract
We conducted a systematic review and network meta-analysis (NMA) to examine the efficacy and completion rates of treatments for latent tuberculosis infection (LTBI). While a previous review found newer, short-duration regimens to be effective, several included studies did not confirm LTBI, and analyses did not account for variable follow-up or assess completion. We searched MEDLINE, Embase, CENTRAL, PubMed, and additional sources to identify RCTs in patients with confirmed LTBI that involved a regimen of interest and reported on efficacy or completion. Regimens of interest included isoniazid (INH) with rifapentine once weekly for 12 weeks (INH/RPT-3), 6 and 9 months of daily INH (INH-6; INH-9), 3–4 months daily INH plus rifampicin (INH/RFMP 3–4), and 4 months daily rifampicin alone (RFMP-4). NMAs were performed to compare regimens for both endpoints. Sixteen RCTs (n = 44,149) and 14 RCTs (n = 44,128) were included in analyses of efficacy and completion. Studies were published between 1968 and 2015, and there was diversity in patient age and comorbidities. All regimens of interest except INH-9 showed significant benefits in preventing active TB compared to placebo. Comparisons between active regimens did not reveal significant differences. While definitions of regimen completion varied across studies, regimens of 3–4 months were associated with a greater likelihood of adequate completion. Most of the active regimens showed an ability to reduce the risk of active TB relative to no treatment, however important differences between active regimens were not found. Shorter rifamycin-based regimens may offer comparable benefits to longer INH regimens. Regimens of 3–4 months duration are more likely to be completed than longer regimens.Keywords
Funding Information
- Canadian Institutes of Health Research (CA) (DNM-137713)
This publication has 49 references indexed in Scilit:
- Isoniazid vs. Rifampin for Latent Tuberculosis Infection in Jail InmatesJournal of Correctional Health Care, 2012
- Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic ReviewsInternational Journal of Epidemiology, 2012
- Three Months of Rifapentine and Isoniazid for Latent Tuberculosis InfectionNew England Journal of Medicine, 2011
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- New Regimens to Prevent Tuberculosis in Adults with HIV InfectionNew England Journal of Medicine, 2011
- An evidence-based practice guideline for the peer review of electronic search strategiesJournal of Clinical Epidemiology, 2009
- LTBI: latent tuberculosis infection or lasting immune responses toM. tuberculosis? A TBNET consensus statementEuropean Respiratory Journal, 2009
- The Effectiveness of a 9-Month Regimen of Isoniazid Alone versus 3- and 4-Month Regimens of Isoniazid plus Rifampin for Treatment of Latent Tuberculosis Infection in Children: Results of an 11-Year Randomized StudyClinical Infectious Diseases, 2007
- Hepatotoxicity of Rifampin and Pyrazinamide in the Treatment of Latent Tuberculosis Infection in HIV-Infected Persons: Is It Different Than in HIV-Uninfected Persons?Clinical Infectious Diseases, 2004
- Isoniazid Chemoprophylaxis of Latent Primary Tuberculosis: in Five Trial Centres in France from 1959 to 1969International Journal of Epidemiology, 1973